Shire Rejects Multiple Equity-Loaded Takeda Offers, Allergan Declines To Bid

Takeda's most recent offer for Shire had an estimated total value of $61bn, but likely included too much equity and too little cash. The companies continue negotiating as an April 25 deadline looms, while Allergan stated it won't bid for Shire.